8-K: Intelligent Bio Solutions Partners with CenExel for FDA 510(k) Clinical Study

Intelligent Bio Solutions has partnered with CenExel to conduct a method comparison clinical study, a key step in their FDA 510(k) submission process for their fingerprint drug screening system.

Summary

• Intelligent Bio Solutions (INBS) has announced a partnership with CenExel, a clinical research site network, to conduct a method comparison study.
• This study is part of INBS's FDA 510(k) clinical study plan for their Intelligent Fingerprinting Drug Screening System.
• The study will involve 135 healthy adult subjects across three sites and will compare fingerprint sweat opiate screening results to results from a liquid chromatography mass spectrometry (LC-MS/MS) method.
• The company aims to demonstrate that their system accurately detects the presence of opiates in the hands of intended users.
• The method comparison study is scheduled to begin in August 2024.
• INBS is targeting a 510(k) submission to the FDA in the fourth quarter of this calendar year.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook with a clear path towards FDA approval. The partnership with CenExel and the planned study commencement are strong indicators of progress. The company is on track with its timeline.

Positives

• The partnership with CenExel provides access to a reputable clinical research network.
• The method comparison study is a significant step towards FDA approval.
• The company is on track for its planned FDA submission in the fourth quarter of this year.
• The technology offers rapid, non-invasive testing with results in under ten minutes.
• The system has potential for broader applications beyond opiate screening.

Risks

• The company's ability to successfully develop and commercialize its drug and diagnostic tests is subject to risks and uncertainties.
• The company's ability to secure regulatory approvals is not guaranteed.
• The company's expectations may prove to be materially different from the results expressed or implied by forward-looking statements.

Future Outlook

The company is focused on completing the method comparison study and submitting its 510(k) application to the FDA in the fourth quarter of 2024. They also see potential for broader applications of their biosensor platform.

Management Comments

• Harry Simeonidis, President and CEO of Intelligent Bio Solutions, stated that the partnership with CenExel and the initiation of the method comparison study marks the final phase in their clinical study plan.
• Harry Simeonidis also mentioned that they are steadily getting closer to filing their 510(k) submission with the FDA.
• Stuart Goldblatt, Chief Executive Officer at CenExel, expressed excitement about commencing the clinical trial to test the innovative device.

Industry Context

This announcement is relevant to the medical technology industry, particularly in the area of rapid, non-invasive drug testing. The partnership with CenExel highlights the importance of clinical validation in the regulatory approval process. The technology competes with traditional drug testing methods and other point-of-care testing solutions.

Comparison to Industry Standards

• The use of LC-MS/MS as a gold standard for comparison is a common practice in drug testing validation studies, ensuring the accuracy of the new method.
• The study design, involving 135 subjects across three sites, is typical for a method comparison study seeking FDA approval.
• Companies like Abbott and Roche also develop point-of-care diagnostic devices, but Intelligent Bio Solutions is focusing on fingerprint sweat analysis, which is a unique approach.
• The company's claim of results in under ten minutes is competitive with other rapid testing technologies.

Stakeholder Impact

• Shareholders will view this as a positive step towards commercialization.
• Employees will be involved in the execution of the clinical study.
• Potential customers in safety-critical industries will be interested in the rapid testing technology.
• The partnership with CenExel is a positive development for both companies.

Next Steps

• Commence the method comparison study in August 2024.
• Complete the method comparison study.
• Submit the 510(k) application to the FDA in the fourth quarter of 2024.

Key Dates

Keywords

FDA 510(k), clinical study, fingerprint drug screening, opiate testing, CenExel, LC-MS/MS, medical technology, non-invasive testing, Intelligent Bio Solutions